MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517046446 A) filed by Daiichi Sankyo Company Limited, Tokyo, on May 14, for 'anti cd25 antibody and anti cd25 antibody drug conjugate.'
Inventor(s) include Sawano Kota; Doke Yukiko; Isumi Yoshitaka; and Matsumoto Ryota.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The present invention addresses the problem of providing: an antibody that binds to CD25 and has an internalization activity; an antibody drug conjugate which contains said antibody and has an anti tumor activity; a medicine which includes said antibody drug conjugate and has a therapeutic effect on tumors; and a method for treating a tumor using said antibody said antibody drug conjugate or said medicine. Provided is a CD25 antibody or an antigen binding fragment of the antibody characterized by (1) not having an IL 2 blocking ability and (2) having an internalization activity into CD25 expressing cells by binding to CD25. The antibody or antigen binding fragment of the antibody can be conjugated with a cytotoxically active compound to exhibit ability to remove regulatory T cells and/or ability to promote proliferation of granzyme positive CD8 positive cells."
The patent application was internationally filed on Mar. 28, 2024, under International application No.PCT/JP2024/012855.
Disclaimer: Curated by HT Syndication.
